Taysha Gene Therapies, Inc. (TSHA) Operating margin 2022–2025
Taysha Gene Therapies, Inc. (TSHA) operating margin by fiscal year — reported operating income divided by reported revenue.
-1130.6%FY2025 · since FY2022: -6492.7% → -1130.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -1130.6% | -33.1 pp |
| FY2024 | -1097.6% | -628.7 pp |
| FY2023 | -468.8% | +6023.9 pp |
| FY2022 | -6492.7% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More TSHA financial trends
TSHA RevenueTSHA Net incomeTSHA Net marginTSHA Gross profitTSHA Gross marginTSHA Operating incomeTSHA Operating cash flowTSHA Free cash flowTSHA Capital expendituresTSHA Return on equityTSHA Stock buybacksTSHA Dividends paidTSHA Total assetsTSHA Total liabilitiesTSHA Shareholders’ equityTSHA overview →